Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1934 1
1960 1
1975 1
1983 1
1984 1
1989 1
1990 1
1997 2
1998 2
1999 2
2000 1
2001 3
2002 2
2003 1
2004 3
2005 3
2006 5
2007 3
2008 2
2009 9
2010 6
2011 4
2012 11
2013 3
2014 8
2015 11
2016 8
2017 4
2018 5
2019 6
2020 9
2021 15
2022 5
2023 10
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

138 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.
Cholesterol Treatment Trialists’ (CTT) Collaboration; Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Cholesterol Treatment Trialists’ (CTT) Collaboration, et al. Lancet. 2010 Nov 13;376(9753):1670-81. doi: 10.1016/S0140-6736(10)61350-5. Epub 2010 Nov 8. Lancet. 2010. PMID: 21067804 Free PMC article.
For each type of trial, we calculated not only the average risk reduction, but also the average risk reduction per 1.0 mmol/L LDL cholesterol reduction at 1 year after randomisation. FINDINGS: In the trials of more versus less intensive statin therapy, the weighted mean fu …
For each type of trial, we calculated not only the average risk reduction, but also the average risk reduction per 1.0 mmol/L LDL cho …
Vitamin D and brain health: an observational and Mendelian randomization study.
Navale SS, Mulugeta A, Zhou A, Llewellyn DJ, Hyppönen E. Navale SS, et al. Am J Clin Nutr. 2022 Aug 4;116(2):531-540. doi: 10.1093/ajcn/nqac107. Am J Clin Nutr. 2022. PMID: 35451454 Free PMC article.
RESULTS: Associations between 25(OH)D and total, gray matter, white matter, and hippocampal volumes were nonlinear, with lower volumes both for low and high concentrations (adjusted P-nonlinear 0.04). 25(OH)D had an inverse association with white matter hyperintensity volume [per …
RESULTS: Associations between 25(OH)D and total, gray matter, white matter, and hippocampal volumes were nonlinear, with lower volumes both …
Dementia prevention in memory clinics: recommendations from the European task force for brain health services.
Frisoni GB, Altomare D, Ribaldi F, Villain N, Brayne C, Mukadam N, Abramowicz M, Barkhof F, Berthier M, Bieler-Aeschlimann M, Blennow K, Brioschi Guevara A, Carrera E, Chételat G, Csajka C, Demonet JF, Dodich A, Garibotto V, Georges J, Hurst S, Jessen F, Kivipelto M, Llewellyn DJ, McWhirter L, Milne R, Minguillón C, Miniussi C, Molinuevo JL, Nilsson PM, Noyce A, Ranson JM, Grau-Rivera O, Schott JM, Solomon A, Stephen R, van der Flier W, van Duijn C, Vellas B, Visser LNC, Cummings JL, Scheltens P, Ritchie C, Dubois B. Frisoni GB, et al. Lancet Reg Health Eur. 2023 Jan 31;26:100576. doi: 10.1016/j.lanepe.2022.100576. eCollection 2023 Mar. Lancet Reg Health Eur. 2023. PMID: 36895446 Free PMC article. Review.
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials.
Cholesterol Treatment Trialists' (CTT) Collaborators; Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, Gray A, Collins R, Baigent C. Cholesterol Treatment Trialists' (CTT) Collaborators, et al. Lancet. 2012 Aug 11;380(9841):581-90. doi: 10.1016/S0140-6736(12)60367-5. Epub 2012 May 17. Lancet. 2012. PMID: 22607822 Free PMC article.
METHODS: This meta-analysis included individual participant data from 22 trials of statin versus control (n=134,537; mean LDL cholesterol difference 1.08 mmol/L; median follow-up 4.8 years) and five trials of more versus less statin (n=39,612; difference 0.51 mmol/L
METHODS: This meta-analysis included individual participant data from 22 trials of statin versus control (n=134,537; mean LDL cholesterol di …
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group. RECOVERY Collaborative Group. Lancet. 2021 May 1;397(10285):1637-1645. doi: 10.1016/S0140-6736(21)00676-0. Lancet. 2021. PMID: 33933206 Free PMC article. Clinical Trial.
Those trial participants with hypoxia (oxygen saturation <92% on air or requiring oxygen therapy) and evidence of systemic inflammation (C-reactive protein 75 mg/L) were eligible for random assignment in a 1:1 ratio to usual standard of care alone versus usual standard …
Those trial participants with hypoxia (oxygen saturation <92% on air or requiring oxygen therapy) and evidence of systemic inflammation ( …
Modifiable risk factors for dementia and dementia risk profiling. A user manual for Brain Health Services-part 2 of 6.
Ranson JM, Rittman T, Hayat S, Brayne C, Jessen F, Blennow K, van Duijn C, Barkhof F, Tang E, Mummery CJ, Stephan BCM, Altomare D, Frisoni GB, Ribaldi F, Molinuevo JL, Scheltens P, Llewellyn DJ; European Task Force for Brain Health Services. Ranson JM, et al. Alzheimers Res Ther. 2021 Oct 11;13(1):169. doi: 10.1186/s13195-021-00895-4. Alzheimers Res Ther. 2021. PMID: 34635138 Free PMC article. Review.
Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity.
Chen SH, Dominik PK, Stanfield J, Ding S, Yang W, Kurd N, Llewellyn R, Heyen J, Wang C, Melton Z, Van Blarcom T, Lindquist KC, Chaparro-Riggers J, Salek-Ardakani S. Chen SH, et al. J Immunother Cancer. 2021 Oct;9(10):e003464. doi: 10.1136/jitc-2021-003464. J Immunother Cancer. 2021. PMID: 34599020 Free PMC article.
CONCLUSION: These findings provide novel mechanistic insights into how myeloid and T cells can be uniquely modulated by the dual innate and adaptive checkpoint antibody and demonstrate its potential in clinical development (NCT04881045) to improve patient outcomes over current PD …
CONCLUSION: These findings provide novel mechanistic insights into how myeloid and T cells can be uniquely modulated by the dual innate and …
Artificial intelligence for biomarker discovery in Alzheimer's disease and dementia.
Winchester LM, Harshfield EL, Shi L, Badhwar A, Khleifat AA, Clarke N, Dehsarvi A, Lengyel I, Lourida I, Madan CR, Marzi SJ, Proitsi P, Rajkumar AP, Rittman T, Silajdžić E, Tamburin S, Ranson JM, Llewellyn DJ. Winchester LM, et al. Alzheimers Dement. 2023 Dec;19(12):5860-5871. doi: 10.1002/alz.13390. Epub 2023 Aug 31. Alzheimers Dement. 2023. PMID: 37654029 Review.
Artificial intelligence for dementia research methods optimization.
Bucholc M, James C, Khleifat AA, Badhwar A, Clarke N, Dehsarvi A, Madan CR, Marzi SJ, Shand C, Schilder BM, Tamburin S, Tantiangco HM; Deep Dementia Phenotyping (DEMON) Network; Lourida I, Llewellyn DJ, Ranson JM. Bucholc M, et al. Alzheimers Dement. 2023 Dec;19(12):5934-5951. doi: 10.1002/alz.13441. Epub 2023 Aug 28. Alzheimers Dement. 2023. PMID: 37639369 Free article. Review.
Artificial intelligence for diagnostic and prognostic neuroimaging in dementia: A systematic review.
Borchert RJ, Azevedo T, Badhwar A, Bernal J, Betts M, Bruffaerts R, Burkhart MC, Dewachter I, Gellersen HM, Low A, Lourida I, Machado L, Madan CR, Malpetti M, Mejia J, Michopoulou S, Muñoz-Neira C, Pepys J, Peres M, Phillips V, Ramanan S, Tamburin S, Tantiangco HM, Thakur L, Tomassini A, Vipin A, Tang E, Newby D; Deep Dementia Phenotyping (DEMON) Network; Ranson JM, Llewellyn DJ, Veldsman M, Rittman T. Borchert RJ, et al. Alzheimers Dement. 2023 Dec;19(12):5885-5904. doi: 10.1002/alz.13412. Epub 2023 Aug 10. Alzheimers Dement. 2023. PMID: 37563912 Review.
138 results